Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid

Journal of Neuroimmunology

Volumn 39, Issue 1-2, 1992, Pages 81-89

  Warren, Kenneth G ^a   Catz, Ingrid ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Antibody; Cerebrospinal fluid; Myelin basic protein; Synthetic peptide

Indexed keywords

MYELIN BASIC PROTEIN; SYNTHETIC PEPTIDE;

ADULT; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANTIBODIES; ANTIBODY SPECIFICITY; HUMAN; MOLECULAR SEQUENCE DATA; MULTIPLE SCLEROSIS; MYELIN BASIC PROTEINS; NEUROPEPTIDES; SUPPORT, NON-U.S. GOV'T;

EID: 0026729074     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/0165-5728(92)90177-M     Document Type: Article

References (42)

1. An improved radioimmunoassay for myelin basic protein-like immunoreactive material in cerebrospinal fluid
2. Characterization of myelin basic protein catabolism products in the cerebrospinal fluid from multiple sclerosis, stroke and head injury patients
3. Myelin basic protein administration in multiple sclerosis
4. Intrathecal synthesis of autoantibodies to myelin basic protein in multiple sclerosis
5. Failure to detect antibodies to myelin basic protein or peptic fragments of of myelin basic protein in CSF of patients with MS
6. Immunoblot detection of oligoclonal anti-myelin basic protein IgG antibodies in cerebrospinal fluid in multiple sclerosis
7. Myelin basic protein: a component of circulating immune complexes in multiple sclerosis
8. Large scale preparation of myelin basic protein from central nervous tissue of several mammalian species
9. Serum and cerebrospinal fluid antibodies against myelin basic protein and their IgG subclass distribution in multiple sclerosis
10. Failure of basic protein therapy for multiple sclerosis
11. CSF antibodies to myelin basic protein and oligodendrocytes in multiple sclerosis and other neurological diseases
12. Preparation and properties of monoclonal antibodies to myelin basic protein and its peptides
13. New monoclonal antibodies reactive with defined epitopes in human myelin basic protein
14. Measurement of immunoreactive myelin basic protein peptide (45–89) in cerebrospinal fluid
15. Sites in myelin basic protein that react with monoclonal antibodies
16. Monoclonal antibodies reactive with myelin basic protein
17. Cell-mediated immunity to myelin-associated glycoprotein; proteolipid protein and myelin basic protein in multiple sclerosis
18. Principles of albumin and IgG synthesis in neurological disorders. II: Evaluation of IgG synthesis within the central nervous system in multiple sclerosis
19. B cells and antibodies in MS
20. Persistent anti-myelin basic protein IgG antibody response in multiple sclerosis cerebrospinal fluid
21. Preferential recognition of peptide 70–89 by anti-MBP Ab-producing cells in CSF of MS patients
22. Antibodies to myelin-associated glycoprotein (MAG) in cerebrospinal fluid of multiple sclerosis patients
23. Antimyelin basic protein and anti-myelin antibody producing cells in multiple sclerosis
24. Antibody to myelin basic protein in patients with multiple sclerosis and subacute sclerosing panencephalitis
25. A study of myelin basic protein as a therapeutic probe in patients with multiple sclerosis
26. Problems of experimental trials of therapy in multiple sclerosis
27. Autoreative T and B cells reproducing to myelin proteolipid protein in multiple sclerosis and controls
28. T and B cell responses to myelin-oligodendiocyte glycoprotein in multiple sclerosis
29. On cerebrospinal fluid immunoglobulin G (IgG) quotients in multiple sclerosis and other diseases
30. Multiple sclerosis: The blood brain barrier and the measurement of de novo central nervous system IgG synthesis. Part II
31. Protection against experimental allergic encephalomyelitis: idiotypic autorelation induced by a non-encephalitogenic T cell clone expressing a cross-reactive T cell receptor V gene
32. CSF antibodies to myelin basic protein and to myelin-associated glycoprotein in multiple sclerosis. Evidence of intrathecal production of autoantibodies
33. The cerebrospinal fluid in multiple sclerosis
34. The relationship between levels of cerebrospinal fluid myelin basic protein and IgG measurement in patients with multiple sclerosis
35. Diagnostic value of cerebrospinal fluid anti-myelin basic protein in patients with multiple sclerosis
36. A correlation between cerebrospinal fluid myelin basic protein and anti-myelin basic protein in multiple sclerosis patients
37. Neutralization of anti-myelin basic protein by cerebrospinal fluid of multiple sclerosis patients in clinical remission
38. Cerebrospinal fluid autoantibodies to myelin basic protein in multiple sclerosis patients. Detection during first exacerbations and kinetics of acute relapses and subsequent convalescent phases
39. A myelin basic protein antibody cascade in purified IgG from cerebrospinal fluid of multiple sclerosis patients
40. Purification of autoantibodies to myelin basic protein by antigen specific chromatography from cerebrospinal fluid IgG of multiple sclerosis patients Immunoreactivity studies with human myelin basic protein
41. Cerebrospinal fluid antibodies to myelin basic protein in acute idiopathic optic neuritis
42. Human myelin basic protein peptide 69–89: immunochemical features and use in immunoassay of cerebrospinal fluid